The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs

The large-scale genetic profiling of tumours can identify potentially actionable molecular variants for which approved anticancer drugs are available1–3. However, when patients with such variants are treated with drugs outside of their approved label, successes and failures of targeted therapy are not systematically collected or shared. We therefore initiated the Drug Rediscovery protocol, an adaptive, precision-oncology trial that aims to...